Hester Biosciences Limited has informed the Exchange regarding a press release dated May 09, 2025, titled "20250509 Q4 & FY25 Press Release".
HESTERBIO · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Hester Biosciences reported its audited financial results for Q4 and FY25. On a standalone basis, total divisional product sales grew 12% for FY25 and 5% in Q4, driven by 16% growth in the Poultry Healthcare division and 6% growth in the Animal Healthcare division. Standalone PAT rose 17% for the full year and 30% in Q4, with EBITDA up 8% in both periods and EBITDA margin improving by 1 percentage point to 19%. On a consolidated basis, full-year PAT grew 36%, though Q4 consolidated PAT fell sharply by 76% and Q4 EBITDA margin compressed by 9 percentage points, weighed down by Hester Africa operations, though Africa's net loss narrowed to INR 102.69 million from INR 182.95 million. The board recommended a dividend of ₹7 per share (70%) for FY25 and statutory auditors issued an unmodified (clean) opinion on the results. Shah & Shah Associates was appointed as Secretarial Auditor for FY2025-26 to FY2029-30.
Positive for shareholders given steady growth in core divisions, healthy standalone margins, and a strong 70% dividend, though the sharp drop in consolidated Q4 PAT and margin compression at the Africa subsidiary may temper short-term sentiment. The clean audit opinion and clear growth pipeline (Avian Influenza vaccine launch, Africa expansion) support a constructive medium-term outlook.